Related Experiment Video
Updated: Apr 3, 2026
Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
Disease-proportional proteasomal degradation of missense dystrophins
Dana M Talsness1, Joseph J Belanto1, James M Ervasti2
1Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota-Twin Cities, Minneapolis, MN 55455.
Abstract:
The 427-kDa protein dystrophin is expressed in striated muscle where it physically links the interior of muscle fibers to the extracellular matrix. A range of mutations in the DMD gene encoding dystrophin lead to a severe muscular dystrophy known as Duchenne (DMD) or a typically milder form known as Becker (BMD). Patients with nonsense mutations in dystrophin are specifically targeted by stop codon read-through drugs, whereas out-of-frame deletions and insertions are targeted by exon-skipping therapies. Both treatment strategies are currently in clinical trials. Dystrophin missense mutations, however, cause a wide range of phenotypic severity in patients. The molecular and cellular consequences of such mutations are not well understood, and there are no therapies specifically targeting this genotype. Here, we have modeled two representative missense mutations, L54R and L172H, causing DMD and BMD, respectively, in full-length dystrophin. In vitro, the mutation associated with the mild phenotype (L172H) caused a minor decrease in tertiary stability, whereas the L54R mutation associated with a severe phenotype had a more dramatic effect. When stably expressed in mammalian muscle cells, the mutations caused steady-state decreases in dystrophin protein levels inversely proportional to the tertiary stability and directly caused by proteasomal degradation. Both proteasome inhibitors and heat shock activators were able to increase mutant dystrophin to WT levels, establishing the new cell lines as a platform to screen for potential therapeutics personalized to patients with destabilized dystrophin.
Insights
Missense mutations in dystrophin cause varying muscular dystrophy severity. Researchers modeled these mutations, finding protein instability and degradation, and identified potential therapeutic strategies targeting proteasomal pathways.
Area of Science:
- Biochemistry
- Genetics
- Cell Biology
Background:
- Dystrophin protein is crucial for muscle fiber integrity, linking the cytoskeleton to the extracellular matrix.
- Mutations in the DMD gene cause Duchenne (DMD) and Becker (BMD) muscular dystrophies, with missense mutations presenting diverse clinical severities.
- Current therapies target nonsense and out-of-frame mutations, but missense mutations lack specific treatments due to poorly understood consequences.
Purpose of the Study:
- To investigate the molecular and cellular effects of two distinct dystrophin missense mutations (L54R and L172H) associated with DMD and BMD.
- To understand the relationship between protein stability, degradation, and disease severity in dystrophinopathies.
- To establish a cellular model for screening potential therapeutics for missense dystrophin mutations.
Main Methods:
- Modeling of full-length dystrophin with specific missense mutations (L54R, L172H).
- In vitro assessment of protein tertiary stability for mutated dystrophin.
- Stable expression of mutant dystrophin in mammalian muscle cells to analyze protein levels and degradation pathways.
- Treatment of cell lines with proteasome inhibitors and heat shock activators.
Main Results:
- The L54R mutation (severe DMD) significantly reduced dystrophin tertiary stability, while L172H (milder BMD) had a minor effect.
- Mutant dystrophin levels decreased proportionally to reduced stability, primarily due to proteasomal degradation.
- Proteasome inhibitors and heat shock activators successfully restored mutant dystrophin levels to wild-type (WT) levels.
Conclusions:
- Missense dystrophin mutations impact protein stability and promote degradation via the proteasome.
- The degree of stability loss correlates with disease severity.
- Developed cell lines serve as a platform for screening drugs that stabilize mutant dystrophin, offering personalized therapeutic potential.
Related Concept Videos
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
01:21Satellite Stem Cells and Muscular Dystrophy
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
02:58Regulated Protein Degradation